B7-H3
Showing 1 - 25 of >10,000
CNS Tumors, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant Trial in Memphis (B7-H3-CAR T cells)
Not yet recruiting
- Central Nervous System Neoplasms
- +6 more
- B7-H3-CAR T cells
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Apr 18, 2023
Soluble B7-H3 as a Biomarker for Osteosarcoma
Recruiting
- Biomarker
- +3 more
- ELISA: enzyme-linked immunosorbent assay
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jul 5, 2023
Advanced Glioma, Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy Trial in Suzhou (Targeted IL-13 Ra2 UCAR-T cell
Recruiting
- Advanced Glioma
- Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy
- Targeted IL-13 Rα2 UCAR-T cell injection
- Targeted B7-H3 UCAR-T cell injection
-
Suzhou, Jiangsu, ChinaThe Second Affiliated Hospital of Soochow University
Mar 2, 2023
Recurrent Glioblastoma, Refractory Glioblastoma Trial in Hangzhou, Huzhou, Ningbo (Temozolomide, B7-H3 CAR-T)
Recruiting
- Recurrent Glioblastoma
- Refractory Glioblastoma
- Temozolomide
- B7-H3 CAR-T
-
Hangzhou, Zhejiang, China
- +2 more
Dec 25, 2022
Glioblastoma Multiforme Trial in Chapel Hill (CAR.B7-H3T cells infusion)
Recruiting
- Glioblastoma Multiforme
- CAR.B7-H3T cells infusion
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Oct 25, 2022
Brain Gliomas Trial in Suzhou (Allogenic B7H3 CAR-?dT cell)
Recruiting
- Brain Gliomas
- Allogenic B7H3 CAR-γδT cell
-
Suzhou, Jiangsu, ChinaDushu Lake Hospital Affiliated to Soochow University
Aug 25, 2023
Brain and Nervous System Trial in Palo Alto (B7-H3CART)
Recruiting
- Brain and Nervous System
-
Palo Alto, CaliforniaStanford Cancer Institute
Jul 22, 2022
Advanced Solid Tumor Trial in Lianyungang (KT095 CAR-T injection)
Not yet recruiting
- Advanced Solid Tumor
- KT095 CAR-T injection
-
Lianyungang, Jiangsu, ChinaLianyungang First People's Hospital
Aug 23, 2022
B7-H3-positive Relapsed/ Refractory Neuroblastoma Trial in Tianjin (T cell injection targeting FLT3 chimeric antigen receptor)
Not yet recruiting
- B7-H3-positive Relapsed/ Refractory Neuroblastoma
- T cell injection targeting FLT3 chimeric antigen receptor
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Nov 1, 2022
CNS Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma Trial in Seattle (SCRI-CARB7H3(s); B7H3-specific chimeric
Recruiting
- Central Nervous System Tumor
- +10 more
- SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
-
Seattle, WashingtonSeattle Children's Hospital
Dec 14, 2022
Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma Trial in Memphis (Fludarabine, Cyclophosphamide, MESNA)
Recruiting
- Pediatric Solid Tumor
- +15 more
- Fludarabine
- +3 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jun 30, 2022
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult Trial in Seattle (SC-CAR4BRAIN)
Not yet recruiting
- Diffuse Intrinsic Pontine Glioma
- +4 more
- SC-CAR4BRAIN
-
Seattle, WashingtonSeattle Children's Hospital
Mar 3, 2023
The Role of B7-H4 in Tumor Vaccine
Recruiting
- Glioma
- tumor vaccine
-
Shanghai, Shanghai, ChinaDi Chen
Nov 26, 2023
Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia
- B7-H3 target, CAR gene modified gdT cell injection
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University School of Med
Feb 15, 2023
Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia
- gdT cell injection targeting B7-H3 chimeric antigen receptor
-
Hefei, Anhui, ChinaPersonGen Anke Cellular Therapeutice Co., Ltd.
Jan 31, 2023
EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer Trial in Guangzhou
Recruiting
- EGFR/ B7H3-positive Advanced Lung Cancer
- EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer
- EGFR/B7H3 CAR-T
-
Guangzhou, Guangdong, ChinaSecond Affiliated Hospital of Guangzhou Medical University
Apr 18, 2022
Glioblastoma Trial in Beijing (B7-H3-targeting CAR-T cells)
Recruiting
- Glioblastoma
- B7-H3-targeting CAR-T cells
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital
Feb 11, 2022
Hepatocellular Carcinoma Trial in Xuzhou (fhB7H3.CAR-Ts, Fludarabine, Cyclophosphamide)
Recruiting
- Hepatocellular Carcinoma
- fhB7H3.CAR-Ts
- +2 more
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Apr 5, 2022
Lung Cancer, Cancer, Immunotherapy Trial in Guangzhou (CAR-T cells targeting PSCA, MUC1, TGFß, HER2, Mesothelin, Lewis-Y, GPC3,
Recruiting
- Lung Cancer
- +3 more
- CAR-T cells targeting PSCA, MUC1, TGFβ, HER2, Mesothelin, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2, or B7-H3
-
Guangzhou, Guangdong, China
- +1 more
Nov 26, 2021
Locally Advanced/Metastatic Solid Tumours Trial (BAT8009 for Injection)
Recruiting
- Locally Advanced/Metastatic Solid Tumours
- BAT8009 for Injection
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 25, 2022
Ovarian Cancer Trial in Xuzhou (fhB7H3.CAR-Ts)
Recruiting
- Ovarian Cancer
- fhB7H3.CAR-Ts
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Jan 25, 2022
Bipolar Disorder Trial in Canada (Cannabidiol, Placebo)
Not yet recruiting
- Bipolar Disorder
- Cannabidiol
- Placebo
-
Calgary, Alberta, Canada
- +7 more
May 18, 2023
Mesothelioma, Bladder Cancer, Melanoma Trial in Australia, Canada, United States (MGD009)
Terminated
- Mesothelioma
- +12 more
- MGD009
-
Los Angeles, California
- +19 more
Feb 4, 2022
Endogenous Cushing Syndrome Trial in Edmonton, Halifax, Sherbrooke (Intervention/Treatment)
Active, not recruiting
- Endogenous Cushing Syndrome
-
Edmonton, Alberta, Canada
- +2 more
Nov 9, 2023